Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Nov;131(11):1341-1348.
doi: 10.1007/s00702-024-02801-2. Epub 2024 Jul 5.

Monotherapy with infusion therapies - useful or not?

Petra Bago Rožanković  1   2 , Anders Johansson  3   4 , Klivényi Péter  5 , Ivan Milanov  6 , Per Odin  7   8
Affiliations
Review

Monotherapy with infusion therapies - useful or not?

Petra Bago Rožanković et al. J Neural Transm (Vienna). 2024 Nov.

Abstract

Infusion pump-based therapies are an effective treatment option for patients with advanced Parkinson´s disease. Achieving monotherapy with infusion-based therapies could simplify the treatment regimen, provide better medication adherence, reduce adverse events and drug interactions. This review presents the literature data on the efficacy, safety, and achievability of monotherapy with all available infusion-based therapies, including apomorphine, levodopa-carbidopa-intestinal gel (LCIG), levodopa-entacapone-carbidopa intestinal gel (LECIG), and foslevodopa-foscarbidopa (LDp/CDp). In summary, monotherapy is achievable and effective in most patients on intestinal levodopa infusion therapy and in some patients on apomorphine infusion. There is a need for further investigation of monotherapy compared to polytherapy, especially in new pump treatment options (LECIG and LDp/CDp). Future research should reveal which patients on infusion-based therapies could benefit from monotherapy, including identification of potential baseline predictors of achieving monotherapy in patients treated with specific infusion-based therapies.

Keywords: Advanced parkinson´s disease; Infusion therapies; Monotherapy.

PubMed Disclaimer

References

    1. Aldred J, Freire-Alvarez E, Amelin AV et al (2023) Continuous Subcutaneous Foslevodopa/Foscarbidopa in Parkinson’s Disease: Safety and Efficacy results from a 12-Month, Single-Arm, Open-Label, phase 3 study. Neurol Ther 12:1937–1958. https://doi.org/10.1007/s40120-023-00533-1 - DOI - PubMed - PMC
    1. Aldred J, Henriksen T, Bouchard M, Martínez-Castrillo J, Soileau M, Spiegel A et al (2023b) Efficacy and safety of foslevodopa/foscarbidopa continuous subcutaneous infusion administered as monotherapy in patients with Parkinson’s disease [abstract]. Mov Disord 38 (suppl 1)
    1. Antonini A, Poewe W, Chaudhuri KR, Jech R, Pickut B, Pirtošek Z, Szasz J, Valldeoriola F, Winkler C, Bergmann L, Yegin A, Onuk K, Barch D, Odin P (2017) GLORIA study co-investigators. Levodopa-carbidopa intestinal gel in advanced Parkinson’s: final results of the GLORIA registry. Parkinsonism Relat Disord 45:13–20. https://doi.org/10.1016/j.parkreldis.2017.09.018 - DOI - PubMed
    1. Antonini A, Odin P, Pahwa R et al (2021) The long-term impact of levodopa/carbidopa intestinal gel on ’of’-time in patients with advanced Parkinson’s disease: a systematic review. Adv Ther 38:2854–2890. https://doi.org/10.1007/s12325-021-01747-1 - DOI - PubMed - PMC
    1. Antonini and Jenner (2018) Apomorphine infusion in advanced Parkinson disease. Nat Rev Neurol 14:693–694. https://doi.org/10.1038/s41582-018-0083-y - DOI - PubMed

MeSH terms

LinkOut - more resources